The FDA has approved the first-ever vaccine for respiratory syncytial virus, better known as RSV. The vaccine, Arexvy, made by the company GSK, is designed to be administered by a single shot to adults 60 and over.
The vaccine, Arexvy, made by the company GSK, is designed to be administered by a single shot to adults 60 and over. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will meet in June to decide whether to give an official recommendation. If the recommendation is given, the vaccine will be available for seniors as early as October.RSV is a highly contagious virus that often leads to other, more severe diseases, such as lower respiratory tract disease.
“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, said in a statement.
“RSV certainly is an important disease in the elderly. In some years, the burden of RSV disease comes close to the burden of flu in the elderly. And this is really a wonderful development,” Dr. Ruth Karron, a professor of international health at Johns Hopkins Bloomberg School of Public Health, told CNN.The FDA study featured 25,000 patients, with half receiving the vaccine and half a placebo. The vaccine was found to significantly reduce RSV-associated lower respiratory tract disease by 82.
In one of two other studies featuring Arexvy administered concomitantly with an FDA-approved influenza vaccine, two participants developed acute disseminated encephalomyelitis , one of whom died.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Les mer »
FDA approves first vaccine for RSV, a moment six decades in the making | CNNAfter a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way.
Les mer »
FDA approves first RSV vaccine to protect older adultsUp to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV.
Les mer »
The First Vaccine for RSV Just Got FDA ApprovalIn a large Phase III trial, GlaxoSmithKline's Arexvy substantially reduced people's risk of severe complications from respiratory syncytial virus infection.
Les mer »
FDA approves world’s first RSV vaccine, a shot for older adultsIn a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
Les mer »